HK:1477 Stock Latest News
Company AnnouncementsOcumension Wins NMPA Green Light for Local Production of Uveitis Implant5d ago1477
Company AnnouncementsOcumension Phase III Myopia Drug OT-101 Hits Primary Goal in China Cohort1w ago1477
Company AnnouncementsOcumension’s Glaucoma Drug OT-301 Wins NDA Acceptance in China1M ago1477
Company AnnouncementsOcumension Completes Phase III Patient Enrollment for Alcon-Developed Dry Eye Drug in China2M ago1477
Company AnnouncementsOcumension Advances China Localization of Key Eye Drug as NMPA Accepts Registration2M ago1477
Company AnnouncementsOcumension Advances OT-202 Dry Eye Drug With First Phase III Patient in China2M ago1477Company AnnouncementsOcumension Narrows Loss as Ophthalmic Portfolio Fuels Double-Digit Revenue Growth2M ago1477
Company AnnouncementsOcumension Sets August Board Meeting to Approve Interim Results and Consider Dividend2M ago1477- Company AnnouncementsOcumension Wins China NMPA Nod for OT-502 Post-Surgery Eye Drug4M ago1477
- Company AnnouncementsOcumension CFO Resigns as Company Secretary Role Consolidated Under Chen4M ago1477
Company AnnouncementsOcumension Secures Shareholder Backing at AGM and Refreshes Board Leadership4M ago1477
Company AnnouncementsOcumension Details Board and Committee Structure to Highlight Governance4M ago1477Company AnnouncementsOcumension Sets 2026 AGM to Approve Results, Board Changes and New Share Mandate4M ago1477
Company AnnouncementsOcumension Starts Phase III Trial Enrollment for Presbyopia Drug OT-802 in China5M ago1477
- Company AnnouncementsOcumension grants new share options and awards to bolster talent retention5M ago1477
Company AnnouncementsOcumension Enrolls First Patient in China Phase III Trial for FDA-Approved Dry Eye Drug OT-2117M ago1477
Company AnnouncementsOcumension Nearly Doubles Revenue in 2025 and Turns EBITDA Positive on Ophthalmic Portfolio Growth7M ago1477
Company AnnouncementsOcumension Plans Board Refresh With New Independent Director After Wu’s Retirement7M ago1477
Company AnnouncementsOcumension Sets March Board Meeting to Approve 2025 Results and Mull Dividend7M ago1477Company AnnouncementsOcumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan9M ago1477